Article

Former Merck Unit Works on First Vaccine for Hepatitis C

Merck & Co. (MRK)

Okairos AG, a biotechnology business that sold to venture capital funds in 2007, is seeking to produce the first preventive vaccine for hepatitis C, challenging makers of treatments for the disease.

Okairos has begun a mid-stage study, funded by the U.S. National Institutes of Health, of a gene-based vaccine designed to stimulate the body’s immune system to prevent hepatitis C from taking hold, Chief Operating Officer Tom Woiwode said in a phone interview from the company’s Basel, Switzerland, headquarters.

Read the full story: http://hcp.lv/xJg8Qg

Source: Bloomberg

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
1 expert is featured in this series.
Miriam Freimer, MD
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo